A Phase 1, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of SM07883, a Novel DYRK1a Inhibitor, Following Oral Administration to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs SM 07883 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Samumed Pacific
- 04 Apr 2019 According to a Samumed media release, the company announced that it has dosed the first subject in this phase I study.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 02 Aug 2018 New trial record